Fatty liver-based identification of two distinct hypertriglyceridemic subgroups in familial combined hyperlipidemia

Metabolism: Clinical and Experimental

Volumn 56, Issue 10, 2007, Pages 1311-1317

  Brouwers, Martijn C G J ^a,b   van Greevenbroek, Marleen M J ^a,b   Bilderbeek Beckers, Monique A L ^c   Robertus Teunissen, Margee G ^a,b   van der Kallen, Carla J H ^a,b   Stehouwer, Coen D A ^a,b   de Bruin, Tjerk W A ^a,b  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b MAASTRICHT UNIVERSITY   (Netherlands)

^c VIECURI MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; APOLIPOPROTEIN B; CHOLESTEROL; INSULIN; LIPID; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

ADULT; AGED; ARTICLE; BODY MASS; CONTROLLED STUDY; DISEASE ASSOCIATION; FAMILIAL HYPERLIPEMIA; FATTY LIVER; FEMALE; HUMAN; HYPERTRIGLYCERIDEMIA; INTRAABDOMINAL FAT; LIPID ANALYSIS; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; PRIORITY JOURNAL; ULTRASOUND;

ADIPOSE TISSUE; ALANINE TRANSAMINASE; ANTHROPOMETRY; BODY MASS INDEX; FATTY LIVER; FEMALE; HUMANS; HYPERLIPIDEMIA, FAMILIAL COMBINED; HYPERTRIGLYCERIDEMIA; LIPOPROTEINS, VLDL; LIVER; MALE; MIDDLE AGED; PHENOTYPE; POPULATION;

EID: 34548631472     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.metabol.2007.05.023     Document Type: Article

References (32)

1. Goldstein J.L., Schrott H.G., Hazzard W.R., Bierman E.L., and Motulsky A.G. Hyperlipidemia in coronary heart disease. II. Genetic analysis of lipid levels in 176 families and delineation of a new inherited disorder, combined hyperlipidemia. J Clin Invest 52 (1973) 1544-1568
2. Austin M.A., McKnight B., Edwards K.L., McNeely C.M., Psaty M.J., Psaty B.M., et al. Cardiovascular disease mortality in familial forms of hypertriglyceridemia: a 20-year prospective study. Circulation 101 (2000) 2777-2782
3. Voors-Pette C., and de Bruin T.W. Excess coronary heart disease in familial combined hyperlipidemia, in relation to genetic factors and central obesity. Atherosclerosis. 157 (2001) 481-489
4. Carr M.C., and Brunzell J.D. Abdominal obesity and dyslipidemia in the metabolic syndrome: importance of type 2 diabetes and familial combined hyperlipidemia in coronary artery disease risk. J Clin Endocrinol Metab 89 (2004) 2601-2607
5. Aitman T.J., Godsland I.F., Farren B., Crook D., Wong H.J., and Scott J. Defects of insulin action on fatty acid and carbohydrate metabolism in familial combined hyperlipidemia. Arterioscler Thromb Vasc Biol 17 (1997) 748-754
6. Purnell J.Q., Kahn S.E., Schwartz R.S., and Brunzell J.D. Relationship of insulin sensitivity and apo B levels to intra-abdominal fat in subjects with familial combined hyperlipidemia. Arterioscler Thromb Vasc Biol 21 (2001) 567-572
7. Keulen E.T., Voors-Pette C., and de Bruin T.W. Familial dyslipidemic hypertension syndrome: familial combined hyperlipidemia, and the role of abdominal fat mass. Am J Hypertens 14 (2001) 357-363
8. Ayyobi A.F., McGladdery S.H., McNeely M.J., Austin M.A., Motulsky A.G., and Brunzell J.D. Small, dense LDL and elevated apolipoprotein B are the common characteristics for the three major lipid phenotypes of familial combined hyperlipidemia. Arterioscler Thromb Vasc Biol 23 (2003) 1289-1294
9. Brouwers M.C., Bilderbeek-Beckers M.A., Georgieva A.M., van der Kallen C.J., van Greevenbroek M.M., and de Bruin T.W. Fatty liver is an integral feature of familial combined hyperlipidaemia: relationship with fat distribution and plasma lipids. Clin Sci (Lond) 112 (2007) 123-130
10. Brouwers M.C., Cantor R.M., Kono N., Yoon J.L., van der Kallen C.J., Bilderbeek-Beckers M.A., et al. Heritability and genetic loci of fatty liver in familial combined hyperlipidemia. J Lipid Res 47 (2006) 2799-2807
11. Adiels M., Taskinen M.R., Packard C., Caslake M.J., Soro-Paavonen A., Westerbacka J., et al. Overproduction of large VLDL particles is driven by increased liver fat content in man. Diabetologia 4 (2006) 1-11
12. Venkatesan S., Cullen P., Pacy P., Halliday D., and Scott J. Stable isotopes show a direct relation between VLDL apo B overproduction and serum triglyceride levels and indicate a metabolically and biochemically coherent basis for familial combined hyperlipidemia. Arterioscler Thromb 13 (1993) 1110-1118
13. Kissebah A.H., Alfarsi S., and Adams P.W. Integrated regulation of very low density lipoprotein triglyceride and apolipoprotein-B kinetics in man: normolipemic subjects, familial hypertriglyceridemia and familial combined hyperlipidemia. Metabolism 30 (1981) 856-868
14. Cabezas M.C., de Bruin T.W., Jansen H., Kock L.A., Kortlandt W., and Erkelens D.W. Impaired chylomicron remnant clearance in familial combined hyperlipidemia. Arterioscler Thromb 13 (1993) 804-814
15. Farrell G.C. Drugs and steatohepatitis. Semin Liver Dis 22 (2002) 185-194
16. Stolk R.P., Wink O., Zelissen P.M., Meijer R., van Gils A.P., and Grobbee D.E. Validity and reproducibility of ultrasonography for the measurement of intra-abdominal adipose tissue. Int J Obes Relat Metab Disord 25 (2001) 1346-1351
17. Saverymuttu S.H., Joseph A.E., and Maxwell J.D. Ultrasound scanning in the detection of hepatic fibrosis and steatosis. Br Med J (Clin Res Ed) 292 (1986) 13-15
18. Saadeh S., Younossi Z.M., Remer E.M., Gramlich T., Ong J.P., Hurley M., et al. The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology 123 (2002) 745-750
19. Keulen E.T., Kruijshoop M., Schaper N.C., Hoeks A.P., and de Bruin T.W. Increased intima-media thickness in familial combined hyperlipidemia associated with apolipoprotein B. Arterioscler Thromb Vasc Biol 22 (2002) 283-288
20. Matthews D.R., Hosker J.P., Rudenski A.S., Naylor B.A., Treacher D.F., and Turner R.C. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28 (1985) 412-419
21. Redgrave T.G., Roberts D.C., and West C.E. Separation of plasma lipoproteins by density-gradient ultracentrifugation. Anal Biochem 65 (1975) 42-49
22. Zhao S.P., Bastiaanse E.M., Hau M.F., Smelt A.H., Gevers Leuven J.A., Van der Laarse A., et al. Separation of VLDL subfractions by density gradient ultracentrifugation. J Lab Clin Med 125 (1995) 641-649
23. Karpe F., and Hamsten A. Determination of apolipoproteins B-48 and B-100 in triglyceride-rich lipoproteins by analytical SDS-PAGE. J Lipid Res 35 (1994) 1311-1317
24. Westerbacka J., Corner A., Tiikkainen M., Tamminen M., Vehkavaara S., Hakkinen A.M., et al. Women and men have similar amounts of liver and intra-abdominal fat, despite more subcutaneous fat in women: implications for sex differences in markers of cardiovascular risk. Diabetologia 47 (2004) 1360-1369
25. deBruin T.W., Georgieva A.M., Brouwers M.C., Heitink M.V., van der Kallen C.J., and van Greevenbroek M.M. Radiological evidence of nonalcoholic fatty liver disease in familial combined hyperlipidemia. Am J Med 116 (2004) 847-849
26. Kelley D.E., McKolanis T.M., Hegazi R.A., Kuller L.H., and Kalhan S.C. Fatty liver in type 2 diabetes mellitus: relation to regional adiposity, fatty acids, and insulin resistance. Am J Physiol Endocrinol Metab 285 (2003) E906-E916
27. Malmstrom R., Packard C.J., Caslake M., Bedford D., Stewart P., Yki-Jarvinen H., et al. Defective regulation of triglyceride metabolism by insulin in the liver in NIDDM. Diabetologia 40 (1997) 454-462
28. Malmstrom R., Packard C.J., Watson T.D., Rannikko S., Caslake M., Bedford D., et al. Metabolic basis of hypotriglyceridemic effects of insulin in normal men. Arterioscler Thromb Vasc Biol 17 (1997) 1454-1464
29. Westerbacka J., Lammi K., Hakkinen A.M., Rissanen A., Salminen I., Aro A., et al. Dietary fat content modifies liver fat in overweight nondiabetic subjects. J Clin Endocrinol Metab 90 (2005) 2804-2809
30. Petersen K.F., Dufour S., Befroy D., Lehrke M., Hendler R.E., and Shulman G.I. Reversal of nonalcoholic hepatic steatosis, hepatic insulin resistance, and hyperglycemia by moderate weight reduction in patients with type 2 diabetes. Diabetes 54 (2005) 603-608
31. Neuschwander-Tetri B.A., Brunt E.M., Wehmeier K.R., Oliver D., and Bacon B.R. Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone. Hepatology 38 (2003) 1008-1017
32. Despres J.P., Golay A., and Sjostrom L. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med 353 (2005) 2121-2134